272 results about "Immunity active" patented technology

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody 4F6 for HPV16 type E7 protein detection and application. The heavy chain variable region CDR sequences and the light chain variable region CDR sequences of the antibody are SEQ ID NO.1-3 and SEQ ID NO.4-6 respectively, and the antibody can be specifically combined with HPV16 type E7 protein without cross reaction. A double-antibody sandwich ELISA detection system constructed based on the antibody is combined with a biotin-avidin amplification technology, the sensitivity reaches 100 pg / mL, and the antibody is suitable for rapid detection of the HPV16 type E7 protein in a cervical exfoliated cell sample. The invention further provides the HPV16 type E7 recombinant protein which is obtained through prokaryotic expression and has immunocompetence, and the HPV16 type E7 recombinant protein is applied to antibody screening and detection. Compared with nucleic acid detection, the method has a lower false positive rate, can be used for early screening of cervical cancer and precancerous lesions, and has a good application prospect.

This disclosure provides methods of increasing in vivo transfection efficiency and pharmacologic activity of T cells, by administering multiple small doses within a compact time period of T cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor that recognizes an antigen of a cell against which immune activity is to be directed. Also provided are methods of depleting B cells, and methods of treating B cell-mediated diseases and disorders by depleting B cells and achieving immunological reset, entailing administration of immune cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor recognizing a B cell marker as multiple small doses within a compact time period. The antigen receptor can be a T cell receptor or a chimeric antigen receptor.

An immunogenic fragment of African swine fever virus CD2v protein, a recombinant protein, an immunogenic composition, and a use thereof. The provided immunogenic fragment of African swine fever virus CD2v protein or a variant thereof with immunogenicity can greatly improve the expression quantity while retaining the strong immunocompetence.

The invention provides a fermented feed formula for enhancing animal immune function and a preparation process thereof, and belongs to the field of fermented feed. The preparation process comprises the following steps: preparing the tortoise shell extract; preparing a plant extract; and preparing the fermented feed. The tortoise shell extract and the acacia farnesiana extract are prepared respectively and then added into the fermentation base material to prepare the fermented feed, so that the tortoise shell extract can provide a material basis for proliferation of immune cells and synthesis of immunocompetence substances; the tortoise shell extract creates a good internal environment for normal function exertion of an immune system, in addition, microelements in the tortoise shell extract are matched with bioactive components in the acacia extract, uptake and utilization of the microelements by immune cells are further enhanced, so that the immune regulation effect is more effectively exerted, and the immunity of the human body is improved. The effect of synergistically enhancing the animal immune function is achieved.

The invention provides a polypeptide, a plant immune resistance inducer and a method for improving the disease resistance of plants. The amino acid sequence of the polypeptide is shown as SEQ ID NO: 9, or the polypeptide has more than 75% of homology with the amino acid sequence shown as SEQ ID NO: 9. The problems of poor broad spectrum and poor thermal stability of immunoactive peptides in the prior art can be solved, and the immunoactive peptides are suitable for the field of plant immune anti-inducing peptide agents.

The invention discloses an NK cell culture method with high amplification efficiency in the technical field of NK cells, by constructing a recombinant plasmid pGAPZa-NDUFA8-NDUFB8 and realizing high-efficiency expression and purification of a fusion protein on the basis, the amplification efficiency of the NK cells can be remarkably improved, and by introducing the NDUFA8-NDUFB8 fusion protein, the amplification efficiency of the NK cells is remarkably improved. A sufficient number of active NK cells can be obtained in a short time, and the fusion protein not only promotes cell proliferation, but also maintains high killing ability and immunocompetence of the amplified NK cells.

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

The invention relates to an application of extracellular beta-glucan derived from aureobasidium melanogenum in preparation of a training immunity inducer. By establishing a mouse bone marrow derived macrophages (BMDMs) and zebra fish juvenile fish training immune activation evaluation model, the immunocompetence of extracellular beta-glucan (eBG) derived from aureobasidium melanogenum is evaluated, and it is found that the extracellular beta-glucan has a more remarkable training immune activation effect compared with beta-glucan (cBG) derived from cell walls, and the immunocompetence of the extracellular beta-glucan (eBG) derived from aureobasidium melanogenum is improved. It is proved that the extracellular beta-glucan (eBG) from the melanin-producing aureobasidium is an excellent training immunity inducer and has a good application prospect in the fields of feed addition of bred animals and disease immune prevention and control.

The present invention relates to an immunogenic fragment of a p30 protein of an African swine fever virus, a recombinant protein, an immunogenic composition, and a use. The immunogenic fragment of the p30 protein of the African swine fever virus or a variant having immunogenicity can greatly improve the expression quantity, and can also reserve strong immunocompetence.

Provided are an immunogenic fragment, a recombinant protein, and an immunogenic composition of the African swine fever virus E248R protein, as well as the use thereof. The immunogenic fragment of the African swine fever virus E248R protein or an immunogenic variant thereof can greatly improve expression levels while retaining strong immunological activity.

The invention provides a preparation method of DC cells. The preparation method is especially suitable for rapidly obtaining high-purity and high-functional-activity DC cells. The method comprises the steps of separation from peripheral blood mononuclear cells (PBMC), induction culture, maturation treatment and the like, maturation of the dendritic cells is promoted by introducing an anti-CD47 single-domain antibody or LPS, and the immunocompetence of the dendritic cells is remarkably improved. The method is further applied to preparation of an anti-tumor cell preparation, the capability of activating tumor specific T cells by tumor antigen-loaded DC cells can be remarkably enhanced, and the killing activity of the T cells to tumor cells is improved. The preparation method provided by the invention overcomes the defects in the prior art, has the advantages of high efficiency, safety and stability, and can provide a more reliable cell therapy scheme for tumor immunotherapy.

The invention discloses an enzymolysis preparation method of high-immunocompetence bovine coloctrum peptide, active peptide and application thereof, and belongs to the field of biotechnology and functional foods.The enzymolysis preparation method is characterized by comprising the steps that bovine coloctrum is degreased, trehalose is added into obtained supernate, first stirring is conducted, and first mixed liquid is obtained; wherein the supernate comprises whey protein and Ig; adding medium protease into the first mixed solution for hydrolysis to obtain enzymatic hydrolysate; wherein the enzymatic hydrolysate comprises a mixture of bovine colostrum hydrolyzed peptides, the Ig activity retention rate is larger than or equal to 90% through the targeted protection and directional enzymolysis technology, the beta-lactoglobulin peptide with the synergistic immune enhancement effect is obtained, the Ig and small molecule peptides in the product have the synergistic effect, the body immune regulation capacity and the intestinal immune function are remarkably improved, the immunity of the human body is improved, and the immunity of the human body is improved. The method can be widely applied to the fields of infant formulas, postoperative nutrition, functional drinks and the like.

The invention discloses a foot and mouth disease virus effective antigen inactivation protective agent and application thereof. The protective agent is prepared from the following components in percentage by mass: 0.05 to 20 percent of a structure curing agent, 0.01 to 5 percent of an ion regulator, 0.005 to 1.0 percent of an antioxidant and the balance of water, the protective agent does not influence the inactivation effect in the process of acting on nucleic acid, inhibits folding and unfolding of a protein physical structure, prevents change of a protein space physical structure, improves free energy of protein denaturation, enhances the stability of a virus space physical structure, maintains the integrity of virions, and has a good application prospect. The effects of preserving the immune biological activity of the protein and reducing the loss of viruses in the inactivation process are achieved, so that the foot-and-mouth disease inactivation antigen liquid with high immunogenicity is obtained. Compared with the conventional antigen protection method, the method has the advantages that the virus is protected before the inactivation process is implemented, the production process is advanced, the stability of the effective antigen can be protected to the greatest extent, and support is provided for obtaining an effective antigen solution with high immunocompetence.

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.

The invention discloses a lysozyme-xanthan gum conjugate nano-particle for improving bioavailability of pleurotus eryngii immune active peptide, which is a nano-particle loaded with pleurotus eryngii immune active peptide prepared by taking lysozyme, xanthan gum and pleurotus eryngii immune active peptide as raw materials through a Maillard reaction controllable damp-heat method. Wherein the amino acid sequence of the pleurotus eryngii immune active peptide is LLGVD. By combining the mild and controllable Maillard reaction with the ultrafiltration purification technology, high-proportion and high-activity loading of the pleurotus eryngii immunocompetent peptide is realized under the mild condition, and the structural integrity and immunomodulatory activity of the pleurotus eryngii immunocompetent peptide are effectively maintained; wide application prospects are realized in the aspect of developing functional foods or related products for improving low immunity. The physical stability, the digestion resistance and the potential oral bioavailability of the active peptide are remarkably improved, and the whole process is safe, green and relatively simple and has good amplification potential.

The invention provides ROS (reactive oxygen species) temperature double-sensitive injectable immunocompetence polyamino acid hydrogel and application thereof. The hydrogel can be independently gelled, the drug loading capacity is high and adjustable, and the hydrogel has temperature response, reactive oxygen species (ROS) response and immunostimulatory activity and can be injected. Through temperature response, the hydrogel is in a solution state under a low-temperature condition and is easy to inject, and the hydrogel can be quickly gelatinized under a body temperature condition to locally form a medicine storage cavern, so that the release time of the medicine is prolonged. Due to ROS response, the hydrogel achieves intelligent response to drug release by responding to a high-active oxygen microenvironment of a tumor site, and selective drug release is achieved. Due to the immunocompetence, the hydrogel can positively respond to a high-active-oxygen local microenvironment of a tumor site, R848 is released to stimulate the activity of host immune cells, and the anti-tumor effect is improved. The hydrogel can be simply and conveniently mixed with other treatment drugs for combined treatment, so that the tumor treatment effect is improved.

The invention belongs to the technical field of biology, and particularly relates to application of an ags1 gene segment in regulating monascus exopolysaccharide synthesis. According to the invention, the ags1 gene segment related to synthesis of a mycelium aggregation factor-cell wall alpha-1, 3-glucan is found from monascus for the first time, and experimental research finds that compared with an initial strain, the content of exopolysaccharides in liquid fermentation liquor of monascus recombinant bacteria of which the gene segment is knocked out is remarkably increased, and the content of the exopolysaccharides in the liquid fermentation liquor is remarkably reduced. The content of extracellular polysaccharide in liquid fermentation liquor of monascus recombinant bacteria overexpressing the gene segment is reduced, but the relative content of galactomannan in the extracellular polysaccharide is increased, so that the monascus recombinant bacteria have higher immunocompetence.

The invention provides a tuberculosis mRNA vaccine as well as a preparation method and application thereof. The invention firstly provides an antigen, which comprises the following antigen components: at least one fusion protein or chimeric protein formed by mycobacterium tuberculosis early secretion antigens Ag85A and Ag85B and / or immunocompetence fragments thereof, at least one mycobacterium tuberculosis PE / PPE family antigen Rv1759c (PE-PGRS family protein WAG22) or immunocompetence fragments thereof, and at least one immunocompetence fragment thereof, and at least one mycobacterium tuberculosis latent associated antigen Rv1813c or an immunocompetence fragment thereof; selectively, two or more of these antigens or immunocompetent fragments thereof may form a fusion protein and / or chimeric protein as an antigen component. The mRNA vaccine with multiple antigen components has a more effective effect on prevention of tuberculosis.

The invention belongs to the technical field of biology, and relates to an immunocompetence composition and a pertussis vaccine containing the immunocompetence composition. The immunocompetence composition comprises pertussis Bordetella outer membrane vesicles and attenuated pertussis toxins in a weight ratio of (5-50): (5-25). Effective protective immunity can be triggered in the process of preventing pertussis infection, pertussis bacteria in the lung are effectively eradicated, and bacterial colonization in the trachea and the nasal cavity is remarkably reduced.

The present disclosure provides, inter alia, compounds comprising a universal antibody binding moiety and a targeting moiety. In some embodiments, the provided compounds recruit various types of antibodies to diseased cells (e.g., cancer cells) and induce immune activity to kill such cells. The provided techniques are useful for the treatment of a variety of diseases, including cancer.

The application discloses a method for preparing cell-derived exosomes and products and applications thereof, and the method comprises the following steps: co-culturing immune-activated programmable cells with a stimulating agent with immune-activation effect, and collecting the cell-derived exosomes with immune activity by a natural secretion collection method or an artificial extrusion collection method. The application has safe and controllable local immune activation, and the immune activation strategy based on the exosomes fully overcomes the safety bottleneck of traditional live bacterial preparations in tumor treatment. By replacing live bacteria with engineered exosomes, not only potential risks such as systemic inflammatory response and infection are effectively avoided, but also the local controllability of immune stimulation signals is ensured, the precise activation and directional regulation of tumor region immune cells are realized, the tumor microenvironment is reshaped, the anti-tumor effect is strengthened, and the broad-spectrum cross-tumor potential is verified across models.

Disclosed are an mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one early-secreted antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof; PE / PPE family antigen WAG22 of Mycobacterium tuberculosis or an immunologically active fragment thereof; and at least one latent-related antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which may serve as a prophylactic vaccine for preventing latent activation or as a therapeutic drug for treating active tuberculosis, exhibiting a significant inhibitory effect on Mycobacterium tuberculosis.

The present invention relates to a nucleic acid molecule capable of controlling innate immunity by RNA and, more specifically, to a short duplex hairpin RNA (sdhRNA) that binds to protein kinase R (PKR), which is activated upon recognition of RNA, thereby inhibiting the activity of PKR and suppressing PKR-mediated innate immunity and which, when introduced into the 3'-UTR of mRNA, can increase the expression level of an antigen. The sdhRNA motif according to the present invention inhibits the activity of protein kinase R (PKR) by binding to PKR activated by recognizing RNA. Therefore, when administered into cells in combination with exogenous RNA or as an insert into the 3'-UTR of mRNA, the sdhRNA motif exhibits the effect of reducing RNA-indued PKR activation, mitigating RNA-induced cell death, and downregulating the expression of interferon-stimulated gene (ISG) as well as improving the expression efficiency of a protein encoded by the mRNA. With the effects, the motif is applied to various RNA-based uses, for example, vaccines, in vivo / ex vivo gene therapeutic agents, and the like.

The present application relates to the technical field of molecular biology, and particularly relates to a human parainfluenza virus type I HN recombinant antigen and application thereof. The amino acid sequence of the human parainfluenza virus type I recombinant HN recombinant antigen provided by the present application is shown as SEQ ID NO:1. The amino acid sequence provided by the present application can be efficiently expressed in insect cells, and a stable antigen can be obtained after purification and preparation of the expression product, and the antigen has high immunological activity and can be used for serum specific antibody detection or parainfluenza virus infection diagnosis.

The invention provides an mRNA (messenger ribonucleic acid) pharmaceutical composition for preventing and treating tuberculosis and application of the mRNA pharmaceutical composition. The mRNA pharmaceutical composition for preventing and treating tuberculosis comprises mRNA molecules for coding mycobacterium tuberculosis antigens and pharmaceutically acceptable auxiliary materials, the mycobacterium tuberculosis antigen comprises the following antigen components: at least one mycobacterium tuberculosis early secretion antigen or an immunocompetence fragment thereof; a mycobacterium tuberculosis PE / PPE family antigen Rv3872 or an immunocompetence fragment thereof; and at least one mycobacterium tuberculosis latent associated antigen or an immunocompetent fragment thereof; the mRNA pharmaceutical composition does not include or further includes an mRNA molecule encoding a cytokine. The pharmaceutical composition provided by the invention is used for preparing tuberculosis vaccines, can be used as a prophylactic vaccine for preventing latent activation, can also be used as a therapeutic drug for treating active tuberculosis, and has a remarkable inhibition effect on mycobacterium tuberculosis.

The present invention relates to: a fusion protein comprising an IL-2 protein and a CD80 protein; and a pharmaceutical composition for preventing or treating a cancer comprising chimeric antigen receptor (CAR)-expressing immune cells. When the fusion protein of the present invention is co-administered with the CAR-expressing immune cells, specifically CAR-T cells, immune activity of the CAR-T cells in tumors is enhanced and sustained. Moreover, when the fusion protein of the present invention is administered alone to a subject with recurrent cancer after the CAR-T cells have been administered, reactivation of the administered CAR-T cells may be induced to kill the recurrent cancer cells. Even when cancer cells are re-transplanted in an animal model in which cancer cells have been completely killed by co-administering the CAR-T cells and the fusion protein of the present invention, the immune activity of the CAR-T cells may be maintained for a long period of time by the fusion protein of the present invention, thereby continuously inhibiting the proliferation of the re-transplanted cancer cells. Accordingly, the fusion protein of the present invention not only enhances and prolongs the immune anticancer activity of the CAR-T cells, but also repeatedly reactivates the administered CAR-T cells, thereby maximizing the efficiency of the CAR-T cells as therapeutic cell resources to ultimately significantly improve the survival rate of patients.

Described herein are compositions and methods for treating or preventing skin or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., Demodex), helminths, protozoa (e.g., amebas (e.g., Acanthamoeba or Cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. The compositions and methods include compounds that exhibit immunological activity, keratolytic activity, antihistamine activity, anti-inflammatory activity, and / or other desirable activities. Topical administration of the compositions to the eyelid margin or surrounding area provides therapeutic benefit to patients with ocular surface disorders.

The present invention discloses a metal complex tailed with an immunologically active molecule, as well as its preparation method and application. The metal complex tailed with an immunologically active molecule exhibits significant anticancer activity. On the one hand, the metal complex exerts cytotoxicity against rapidly growing cancer cells through its active ingredient with anti-tumor immune efficacy. On the other hand, it can also induce immunogenic cell death, enabling the host immune system to attack tumor cells and induce a tumor-specific immune response. (The metal complex of the present invention has been shown to effectively induce immunogenic cell death in non-small cell lung cancer cells and successfully activate anti-tumor immunity in mice in vaccine experiments.) Therefore, the metal complex of the present invention has outstanding effects in anti-cancer, anti-inflammatory, inducing immunogenic cell death, and achieving anti-tumor immunity, and has broad application prospects.

The invention discloses a double-target chimeric antigen receptor capable of simultaneously targeting TLL1 and B7H3, a CAR-T cell and application of the double-target chimeric antigen receptor. The chimeric antigen receptor is a fusion protein which is sequentially composed of Omburt-scFv (SEQ ID NO: 1) targeting B7H3, a CD8 alpha hinge region and transmembrane region, a 4-1BB costimulatory domain, a CD3 zeta signal domain and TLL1-scFv (SEQ ID NO: 6) targeting TLL1 from an N terminal to a C terminal. The TLL1-scFv can be efficiently combined with TLL1 protein, can inhibit a TGF-beta signal channel and block prostate cancer cell migration, and is integrated into CAR of targeted B7H3, so that the double-target CAR-T cell with direct killing and immune microenvironment regulation functions is successfully constructed. The CAR-T cell has a remarkable killing effect on a prostate cancer cell line DU145, can be strongly activated after being co-cultured with a target cell and secretes a large amount of IFN-gamma and TNF-alpha, and shows high immunocompetence. The invention provides a new synergistic immunotherapy strategy for the B7H3-positive prostate cancer with the TGF-beta signal channel activated.